参芪扶正注射液联合阿帕替尼和脾多肽注射液治疗晚期原发性肝癌患者的临床研究  

Study on the curative effect of Jieduhuoxue decoction combined with spleen polypeptide injection and apatinib in the treatment of advanced liver cancer

作　　者：魏娟 倪龙刚 陈贤明[1] 汪蕊[2] WEI Juan;NI Long-gang;CEHN Xian-ming;WANG Rui(Cancer Hospital of Huainan Dongfang Hospital Group,Oncology Department(Anhui,Huainan,232035),China;不详)

机构地区：[1]淮南东方医院集团肿瘤医院肿瘤科,安徽淮南232035 [2]蚌埠医学院第一附属医院肿瘤内科

出　　处：《中西医结合肝病杂志》2021年第9期803-805,共3页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

摘　　要：目的:探讨参芪扶正注射液联合阿帕替尼和脾多肽注射液治疗晚期原发性肝癌患者的临床疗效与安全性。方法:选取2017年7月至2020年7月我院收治的晚期原发性肝癌患者90例,随机分为对照组(45例,采用脾多肽注射液联合阿帕替尼治疗)和联合组(45例,在对照组患者治疗基础上加用参芪扶正注射液)。对比两组患者的疗效、肝功能、生活质量,并评估两种方案的安全性。结果:治疗后联合组患者客观有效率(ORR)、疾病控制率(DCR)、KPS评分改善率、QOL评分改善率分别为46.67%、71.11%、91.11%、95.56%,对照组患者分别为37.78%、64.44%、73.33%、75.56%,联合组患者的KPS及QOL评分改善率显著高于对照组(P<0.05)。但两组患者ORR、DCR比较,差异无显著性意义(P>0.05)。治疗后两组患者ALT、AST、TBil、AFP水平均下降,且联合组患者ALT、AST、TBil水平显著低于对照组(P<0.05),AFP水平与对照组比较,差异无显著性意义(P>0.05)。联合组患者蛋白尿、乏力、上腹痛、纳差、手足综合征等不良反应发生率均低于对照组,其中蛋白尿、乏力发生率与对照组比较,差异有统计学意义(P<0.05)。结论:参芪扶正注射液联合脾多肽注射液和阿帕替尼治疗晚期原发性肝癌,可有效改善患者的功能状态、降低肝功能水平,提高患者的生活质量,更好地降低毒副反应的发生风险。Objective:The clinical efficacy and safety of Jieduhuoxue Decoction combined with apatinib and spleen polypeptide injection in the treatment of advanced primary liver cancer.Methods:Ninety patients with advanced primary liver cancer who were admitted and diagnosed in our hospital from July 2017 to July 2020 were randomly divided into a control group(45 cases)treated with spleen polypeptide injection combined with apatiniband a combination group(45 cases)were treated with Jieduhuoxue Decoction on the basis of the control group.The efficacy,liver function,quality of life,and safety assessment of the two groups of patients were compared.Results:The objective response rate(ORR),disease control rate(DCR),KPS score improvement rate,and QOL score improvement rate of the combined group was 46.67%,71.11%,91.11%,95.56%,respectively,and the control group were 37.78%,64.44%,73.33%,and 75.56%.The improvement rate of KPS and QOL scores in the combined group was significantly higher than that in the control group(P<0.05),but there was no significant difference in ORR and DCR between the two groups(P>0.05).Before treatment,there was no significant difference in the levels of ALT,AST,TBil,and AFP between the two groups of patients(P>0.05);after treatment,the levels of ALT,AST,TBil,and AFP decreased in the two groups.The levels of ALT,AST,and TBil in the combined group were compared between the groups Significantly lower than the control group(P<0.05),and the AFP level was not different from the control group(P>0.05).The incidence of adverse reactions such as combined histoneuria,fatigue,epigastric pain,anorexia,and hand-foot syndrome was lower than those of the control group,and the differences in the incidence of proteinuria and fatigue between the groups were statistically significant(P<0.05).Conclusion:Detoxification or blood sugar combined with spleen polypeptide injection and apatinib in the treatment of advanced primary liver cancer can better alleviate the symptoms of patients with upper abdominal pain,anorexia,hand-foot s

关 键 词：原发性肝癌 脾多肽注射液 阿帕替尼 参芪扶正注射液 安全性 

分 类 号：R735.7[医药卫生—肿瘤]